Abdessalem M, Adham S
Oncol Res. 2024; 33(1):27-44.
PMID: 39735681
PMC: 11671623.
DOI: 10.32604/or.2024.056955.
Pessino G, Scotti C, Maggi M, Immuno-Hub Consortium
Cancers (Basel). 2024; 16(5).
PMID: 38473265
PMC: 10931414.
DOI: 10.3390/cancers16050901.
Martin-Gallausiaux C, Salesse L, Garcia-Weber D, Marinelli L, Beguet-Crespel F, Brochard V
Gut Microbes. 2023; 16(1):2295384.
PMID: 38126163
PMC: 10761154.
DOI: 10.1080/19490976.2023.2295384.
Liu C, Peng H, Siao A, Tsuei Y, Lin Y, Shiah S
Exp Biol Med (Maywood). 2023; 248(20):1695-1707.
PMID: 37646261
PMC: 10792425.
DOI: 10.1177/15353702231191206.
Ying J, Zhou H, Wang Z, You Q, Chen J, Lu H
Cancer Cell Int. 2023; 23(1):6.
PMID: 36647071
PMC: 9843993.
DOI: 10.1186/s12935-023-02847-4.
Association of D299G Polymorphism of TLR4 Gene and CagA Virulence Factor of H. pylori among the Iranian Patients with Colorectal Cancer.
Malallah Ghayemi S, Aboutaleb N, Yousefi G, Mousavi-Niri N, Naseroleslami M
Med J Islam Repub Iran. 2022; 36:96.
PMID: 36419946
PMC: 9680813.
DOI: 10.47176/mjiri.36.96.
Role of USP13 in physiology and diseases.
Wang Q, Sun Z, Xia W, Sun L, Du Y, Zhang Y
Front Mol Biosci. 2022; 9:977122.
PMID: 36188217
PMC: 9515447.
DOI: 10.3389/fmolb.2022.977122.
Context-dependent functions of pattern recognition receptors in cancer.
Man S, Jenkins B
Nat Rev Cancer. 2022; 22(7):397-413.
PMID: 35355007
DOI: 10.1038/s41568-022-00462-5.
Peritoneal Modulators of Endometriosis-Associated Ovarian Cancer.
Brunty S, Clower L, Mitchell B, Fleshman T, Bou Zgheib N, Santanam N
Front Oncol. 2021; 11:793297.
PMID: 34900746
PMC: 8655857.
DOI: 10.3389/fonc.2021.793297.
Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.
Farooq M, Batool M, Kim M, Choi S
Front Cell Dev Biol. 2021; 9:756315.
PMID: 34671606
PMC: 8522911.
DOI: 10.3389/fcell.2021.756315.
Identification of TLR2 Signalling Mechanisms Which Contribute to Barrett's and Oesophageal Adenocarcinoma Disease Progression.
Flis E, Barber G, Nulty C, Keogh B, McGuirk P, Anand A
Cancers (Basel). 2021; 13(9).
PMID: 33922955
PMC: 8123271.
DOI: 10.3390/cancers13092065.
The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M, Spillane C, Gallagher M, McCann A, Martin C, Blackshields G
PLoS One. 2020; 15(12):e0243715.
PMID: 33370338
PMC: 7769460.
DOI: 10.1371/journal.pone.0243715.
Hypoxia-Inducible Ubiquitin Specific Peptidase 13 Contributes to Tumor Growth and Metastasis via Enhancing the Toll-Like Receptor 4/Myeloid Differentiation Primary Response Gene 88/Nuclear Factor-κB Pathway in Hepatocellular Carcinoma.
Gao S, Chen T, Li L, Liu X, Liu Y, Zhao J
Front Cell Dev Biol. 2020; 8:587389.
PMID: 33195243
PMC: 7604352.
DOI: 10.3389/fcell.2020.587389.
Modulation of Immune Infiltration of Ovarian Cancer Tumor Microenvironment by Specific Subpopulations of Fibroblasts.
Wang J, Cheng F, Tedrow J, Chang W, Zhang C, Mitra A
Cancers (Basel). 2020; 12(11).
PMID: 33138184
PMC: 7692816.
DOI: 10.3390/cancers12113184.
The prognostic role of tissue TLR2 and TLR4 in colorectal cancer.
Beilmann-Lehtonen I, Bockelman C, Mustonen H, Koskensalo S, Hagstrom J, Haglund C
Virchows Arch. 2020; 477(5):705-715.
PMID: 32424768
PMC: 7581516.
DOI: 10.1007/s00428-020-02833-5.
CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential.
Li J, Alvero A, Nuti S, Tedja R, Roberts C, Pitruzzello M
Oncogene. 2020; 39(20):3965-3979.
PMID: 32205869
PMC: 8343988.
DOI: 10.1038/s41388-020-1269-5.
MyD88 Death-Domain Oligomerization Determines Myddosome Architecture: Implications for Toll-like Receptor Signaling.
Moncrieffe M, Bollschweiler D, Li B, Penczek P, Hopkins L, Bryant C
Structure. 2020; 28(3):281-289.e3.
PMID: 31995744
PMC: 7054835.
DOI: 10.1016/j.str.2020.01.003.
P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study.
Lupi L, Delella F, Cucielo M, Romagnoli G, Kaneno R, da Silva Nunes I
Molecules. 2019; 25(1).
PMID: 31861351
PMC: 6982916.
DOI: 10.3390/molecules25010005.
ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer.
Zanini D, Manfredi L, Pelinson L, Pimentel V, Cardoso A, Carmo Araujo Goncalves V
Med Oncol. 2019; 36(9):78.
PMID: 31375946
DOI: 10.1007/s12032-019-1301-1.
Co-expression of CD44/MyD88 is a poor prognostic factor in advanced epithelial ovarian cancer.
Zhu Y, Zhang H, Zhang G, Shi Y, Huang J
Ann Transl Med. 2019; 7(5):91.
PMID: 31019941
PMC: 6462660.
DOI: 10.21037/atm.2019.01.28.